Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Sartorius Stedim Biotech Expands Portfolio by Adding Cell Culture Media

Published: Friday, December 21, 2012
Last Updated: Friday, December 21, 2012
Bookmark and Share
Sartorius Stedim Biotech assumes global sales and marketing of media and buffer solutions for biopharmaceutical manufacture.

Sartorius Stedim Biotech (SSB), a leading international pharmaceutical and biotech supplier, today announced a substantial expansion of its product array in the cell culture range. The company signed a cooperation agreement with the Swissbased life science group Lonza on long-term, global collaboration in the field of cell culture media. Cell culture media are growth substances and nutrients for cells or microorganisms and are required in every biopharmaceutical manufacturing process.

The cooperation agreement provides that SSB will assume global sales and marketing of Lonza’s media and buffers used in the manufacture of protein-based therapeutics and vaccines, while Lonza will continue to carry out development, manufacture and logistics operations for these products. New product development will be mutually performed. The cell culture media, which are usually sold in liquid or powder form to biopharmaceutical customers, are to be successively converted to packaged forms as ready-to-use, prefilled SSB sterile single-use bags. Furthermore, Lonza and SSB have agreed that these cell culture media will be sold under both brands in a co-branding arrangement.

In fiscal 2011, Lonza generated revenue of around 20 million euros with its cell culture media business. SSB will take over Lonza’s commercial team of approximately 15 media specialists. Both parties have agreed not to disclose further contractual conditions.

Lonza’s cell culture media represent an ideal fit with the portfolio of products supplied by Sartorius Stedim Biotech, which already offers bioreactors and single-use bags and containers as key components for cell cultivation. “I am very pleased that we will now be adding a market-leading, high-quality array of media and buffers to our product offering,” commented SSB’s Member of the Board of Directors, Reinhard Vogt. “Just like our single-use bags and bioreactors, culture media are critical to the success of safe and efficient manufacture of drug materials. The demand for ready-to-use and innovative products is accordingly high. In 2 the manufacture of biologicals, our customers will benefit from obtaining fully integrated single-use solutions for their entire cell culture process all from a single source.”

“For Lonza this agreement provides great upside potential as it will allow us to capture additional value from our Media Business in the form of additional revenue leading to higher capacity utilization”, comments Lukas Utiger, COO of Lonza Bioscience. “Lonza and Sartorius are a great fit as both partners bring complementary strengths to the benefit of our customers.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sartorius Acquires U.S. Start-Up kSep Systems
Transaction to expand SSB’s bioprocessing product portfolio with innovative single-use centrifuges.
Thursday, July 07, 2016
Sartorius Apprenticeship Scheme Honoured
Cambridge regional college awards recognises firm’s outstanding apprenticeship scheme.
Wednesday, March 23, 2016
Sartorius Stedim Biotech and GE Healthcare Sign Worldwide OEM Supply Agreement
Expands GE’s start-to-finish offering for cost efficient manufacture of biopharmaceuticals.
Tuesday, September 01, 2015
Miriam Monge to Join Sartorius Stedim Biotech
Company appoints Miriam Monge as director of marketing for integrated solutions.
Wednesday, August 27, 2014
Sartorius Stedim Announces Offer to Acquire TAP Biosystems
Sartorius Stedim Biotech to further expand its portfolio of single-use fermentors.
Tuesday, October 08, 2013
Sartorius Stedim Biotech’s New Manufacturing Facility in Yauco, Puerto Rico, Receives LEED Platinum Certification
The highest possible rating for ecological and sustainable building design; the world’s first Platinum-certified manufacturing facility to supply the biopharmaceutical industry.
Friday, January 25, 2013
Sartorius Appoints Senior Vice President
Appointment of Stefan Schlack as Senior Vice President of marketing.
Thursday, October 25, 2012
SSB and Bosch Announce Global Collaboration
Agreement covers the mutual design and development of single-use filling solutions.
Thursday, June 21, 2012
SSB and Refine Technology Announce Cooperation
Development of a robust, easy-to-use platform for high-density cell cultivation.
Tuesday, January 24, 2012
SSB and G-Con Manufacturing Announce Global Collaboration
Collaboration will support faster and more flexible facility construction and shortened time to market.
Thursday, January 19, 2012
Sartorius Stedim Biotech and GE Healthcare Life Sciences Sign Cross-Licensing Agreement
Agreement covers intellectual property relating to biopharmaceutical manufacturing technologies.
Monday, September 12, 2011
SSB and Südpack Medica AG Sign Exclusive Cooperation Agreement
Südpack and SSB cooperate in the manufacture of plastic film.
Friday, June 17, 2011
Sartorius Stedim Biotech and RAUMEDIC Sign Partnership Agreement
SSB’s product portfolio to be extended by tubing and polymer components.
Friday, May 20, 2011
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos